JC

James Calloway

Financial Reporter

James Calloway is a financial reporter at StockTi covering corporate earnings, regulatory policy, and market-moving events. A former business journalist with Reuters, James has covered financial markets for over eight years across New York and Washington. He specializes in breaking down earnings reports, SEC filings, and policy decisions that affect publicly traded companies and investor portfolios.

Earnings, Regulation 3,625 articles

Articles by James Calloway

eBay Shares Surge on Q1 Beat and GameStop Acquisition Rumors
Earnings

eBay Shares Surge on Q1 Beat and GameStop Acquisition Rumors

eBay shares rose 9% in extended trading following a Q1 earnings beat and reports that GameStop may make a bid for the online marketplace.

EBAY GME
DocuSign Shares Gain 4% as AI Contract Platform Faces Key Earnings Test
Earnings

DocuSign Shares Gain 4% as AI Contract Platform Faces Key Earnings Test

DocuSign shares climbed 4.3% as the company gears up to report fiscal Q1 results, with the market watching for signs of traction from its AI-driven contract platform.

DOCU
Vanguard Discloses 5.34% Passive Stake in Kraft Heinz Ahead of Q1 Earnings
Earnings

Vanguard Discloses 5.34% Passive Stake in Kraft Heinz Ahead of Q1 Earnings

Vanguard Capital Management disclosed a 5.34% passive stake in Kraft Heinz (KHC), owning 63.3 million shares, ahead of the company's first-quarter earnings report on May 6.

KHC PEP MDLZ
Xanadu Quantum Tech Faces First Earnings Test Since SPAC Debut
Earnings

Xanadu Quantum Tech Faces First Earnings Test Since SPAC Debut

Xanadu Quantum Technologies will report Q1 earnings on May 14, its first since listing via SPAC. Focus is on cash burn and progress toward fault-tolerant quantum computing.

Clorox Shares Tumble 9.6% on Lowered Profit Outlook as Energy Costs, Purell Deal Weigh
Earnings

Clorox Shares Tumble 9.6% on Lowered Profit Outlook as Energy Costs, Purell Deal Weigh

Clorox slashed its fiscal 2026 profit forecast, sending shares down 9.6%. Rising energy costs, ERP stabilization expenses, and the Purell acquisition are pressuring margins.

CLX PG CL
Zoom Shares Rally Ahead of Q1 Earnings, AI Strategy in Focus
Earnings

Zoom Shares Rally Ahead of Q1 Earnings, AI Strategy in Focus

Zoom shares rose 6.6% to $103.60 ahead of its May 21 earnings report. The company's AI push and enterprise growth are key tests for the stock.

ZM
Newell Brands Shares Surge on Upgraded 2026 Forecast Amid Sales Challenges
Earnings

Newell Brands Shares Surge on Upgraded 2026 Forecast Amid Sales Challenges

Newell Brands shares rose about 9% after the company boosted its 2026 sales and earnings outlook, citing stronger-than-expected demand and margins, though core sales still declined 3.5%.

NWL
nVent Electric Surges on Data Center Demand, Raises 2026 Outlook
Earnings

nVent Electric Surges on Data Center Demand, Raises 2026 Outlook

nVent Electric raised its 2026 sales and profit forecasts after Q1 net sales surged 53% to $1.24 billion, driven by data-center demand for liquid cooling and power equipment.

NVT
SoundHound AI Shares Surge Ahead of Q1 Earnings Amid Growth Push
Earnings

SoundHound AI Shares Surge Ahead of Q1 Earnings Amid Growth Push

SoundHound AI shares jumped about 17% to $9.31 ahead of its May 7 Q1 earnings report, as investors assess recent deals for growth potential.

SOUN
Canada Targets Crypto ATMs and Establishes Federal Financial Crimes Agency
Regulation

Canada Targets Crypto ATMs and Establishes Federal Financial Crimes Agency

Canada plans to ban cryptocurrency ATMs and establish a new Financial Crimes Agency with police powers, citing over C$704 million in fraud losses in 2025.

BTBT BTCS
Eaton Stock Pauses After Record High, Q1 Earnings in Focus
Earnings

Eaton Stock Pauses After Record High, Q1 Earnings in Focus

Eaton shares slipped 1.5% after a record high, with Q1 earnings due May 5 expected to test AI-driven data-center demand and margin growth.

ETN
Recursion Pharma Co-Founder Gibson to Exit Board Ahead of Q1 Results
Earnings

Recursion Pharma Co-Founder Gibson to Exit Board Ahead of Q1 Results

Recursion Pharmaceuticals founder Chris Gibson will leave the board at the June annual meeting. Q1 earnings due May 6; focus on cash, clinical progress, and AI platform.

RXRX